Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativa

Australas J Dermatol. 2020 Nov;61(4):e488-e490. doi: 10.1111/ajd.13377. Epub 2020 Jul 6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Dermatologic Agents / adverse effects
  • Dermatologic Agents / therapeutic use*
  • Female
  • Hidradenitis Suppurativa / complications
  • Hidradenitis Suppurativa / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Pain / etiology
  • Quality of Life
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • tildrakizumab